Furthermore, recent evaluation of soluble CAIX (sCAIX) induced by shedding in breast cancer patients treated with bevacizumab showed that sCAIX levels are predictive of therapeutic response to inhibition of angiogenesis [30]. The gene discussed is CA9; the disease is breast cancer.